Skip to main content

Henry Seth Friedman

James B. Powell, Jr. Distinguished Professor of Pediatric Oncology, in the School of Medicine
Neurosurgery, Neuro-Oncology
Box 3624 Med Ctr, Durham, NC 27710
047 Baker House, Durham, NC 27710

Selected Grants


Therapies for Glioblastoma Multiforme

ResearchPrincipal Investigator · Awarded by Jewish Communal Fund · 2022 - 2026

Circle of Service Foundation Challenge Grant

Institutional SupportPrincipal Investigator · Awarded by Circle of Service Foundation · 2023 - 2025

PVSRIPO in melanoma

ResearchCo-Mentor · Awarded by National Cancer Institute · 2020 - 2025

Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas

ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2022

Therapies for Glioblastoma Multiforme

ResearchPrincipal Investigator · Awarded by Jewish Communal Fund · 2007 - 2022

Research Training In Neuro-Oncology

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1998 - 2016

Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide

Clinical TrialCollaborator · Awarded by National Institutes of Health · 2009 - 2014

Gene Targeted Therapy of Brain Tumors

ResearchCollaborator · Awarded by National Institutes of Health · 2009 - 2012

Targeting Brain Tumor Stem Cells

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2011

Research Training In Neuro-Oncology

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 2005 - 2010

Temodar Resistance in CNS Tumors

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 2010

Changes in Functional Status Across Therapy for Primary Gilioma

ResearchConsultant · Awarded by National Cancer Institute · 2006 - 2009

TGFbeta-PTEN Interactions in Glioma Biology & Therapy

ResearchConsultant · Awarded by National Institutes of Health · 2006 - 2008

Molecular Mechanisms of SPARC Mediated Glioma Invasion

ResearchConsultant · Awarded by National Institutes of Health · 2006 - 2008

DNA Methylation and GSTP1 Gene Regulation in Gliomas

ResearchCo Investigator · Awarded by National Institutes of Health · 2002 - 2008

Biomarker Studies for Novel Anti-Cancer Agents

ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2008

Imaging of O6-Alkylguianine-DNA Alkyltransferase

ResearchConsultant · Awarded by National Institutes of Health · 2002 - 2007

Phase II Study of 44Gy from 131I-81C6 for CNS Tumors

ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2006

Astatine-211 & Radioiodine Labeled Octreotide Conjugates

ResearchInvestigator · Awarded by National Institutes of Health · 2001 - 2006

Regional AGT Depletion of CNS and Leptomeningeal Tumors

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2006

AGT Depletion for therapy of CNS tumors

ResearchMentor · Awarded by National Institutes of Health · 2000 - 2005

GCRC CAP

ResearchMentor · Awarded by National Institutes of Health · 2000 - 2005

Therapy of Temodar plus O6-Benzulguanine in Malignant Glioma

ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2005

A Molecular Classification of Brain Tumors

ResearchCo Investigator · Awarded by National Institutes of Health · 2000 - 2003

ZD1839 Therapy of Glioblastoma Multiforme

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2003

Intrathecal Busulfan Therapy of Neoplastic Meningitis

ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 1998 - 2002

GRT-Photo-Documentary/Patients/Brain Tumors

ResearchPrincipal Investigator · Awarded by The Mary Duke Biddle Foundation · 1999 - 2002

Same

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2001

Src On Primary And Matastatic Tumors Of The Cns

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1994 - 1999

Src On Primary And Metastatic Tumors Of The Cns

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1997 - 1999

Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma

Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 1998

Cyclophosphamide Resistance In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 1998

Cyclophosphamide Resistance In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1998

Cyclophoshamide Resistance In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1998

Phase I Trial Of 06-Benzylguanine Plus Bcnu In Glioma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1997

Pediatric Oncology Group Studies

Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 1995 - 1995

Gluathione Modulation Of Alkylators In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1995

Glutathione Modulation Of Alkylators In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1995

Pediatric Oncology Group Studies

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1994

Src On Malignant Human Gliomas And Medulloblastomas

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1993 - 1994

Melphalan Cytotoxicity And Resistance In Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1990 - 1991

Neurobiology And Rational Therapy Of Human Medulloblastoma

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1987 - 1990

Neurobiology And Rational Therapy Of Human Medulloblasto

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1986 - 1990

External Relationships


  • Istari Oncology
  • Leaf Vertical
  • Matrix Capital

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.